Page Comparison

MSH|^~\&|MOADLEDIT^MOADLEDIT:3.1.2 (Build 6381) [win32-i386]^L|Unassigned^8D9FE669-4710-455D-8B97-811508B616E7^GUID|||2016101916242720161102150514+1100||ORU^R01^ORU_R01|XX10191624300XX11021505120-47357859|P|2.4^AUS&Australia&ISO3166_1^HL7AU-OO-201701&&L|||AL|AL|AUS PID|1||8003608833357361^^^AUSHIC^NI~7654321^^^RMH^MR||CITIZEN^GEORGE||19640701|M|||C/o Paradise Close^^NAR NAR GOON^VIC^3812^AUSGOON^VIC^3812^AU PV1|1|O|||||||419786CW^CRUICE^ANTHONY^^^DR^^^AUSHICPR^L^^^UPIN ORC|RE||92D0CE503BE7CECB-173AAD59-4A2F4C46-A3B1B711-6165376F222B^Unassigned^8D9FE6695F6E137C2890^Unassigned^8D9FE669-4710-455D-8B97-811508B616E7^GUID||CM|||||||419786CW^CRUICE^ANTHONY^^^DR^^^AUSHICPR^L^^^UPIN OBR|1||92D0CE503BE7CECB-173AAD59-4A2F4C46-A3B1B711-6165376F222B^Unassigned^8D9FE6695F6E137C2890^Unassigned^8D9FE669-4710-455D-8B97-811508B616E7^GUID|8490884907-3^Prostate5^Colorectal Cancer Structured Pathology Histopathology^LNReport^LN||20161019+1100|2016101920161102+1100|||||||||419786CW^CRUICE^ANTHONY^^^DR^^^AUSHICPR^L^^^UPIN||||LN=92D0CE503BE7CECB-173AAD59-4A2F4C46-A3B1B711-6165376F222B5F6E137C2890||201610191609201611021450+1100||PHYSP|F||^^^20161019^^^20161102+1100|419786CW^CRUICE^ANTHONY^^^DR^^^AUSHICPR^L^^^UPIN~921198YF^SMITH^MICHAEL^^^DR^^^AUSHICPR^L^^^UPIN OBX|1|RP|60572-5^^LN^ENTRY^^EN 13606|1|CEN.RCPA-ProstateCancer_(Rad_Prostatectomy).v2^ProstateColorectalCancer.v3^Colorectal Cancer HistopathologyStructured Pathology Report&99A-F4ADB3A91A8963334DD10FEE7661CBF6&L^TX^OctetL^TEXT^Octet-stream||||||F OBX|2|CE|70949-3^^LN^CLUSTER^^EN 13606|1.1|70949-3^Clinical details^LN||||||F OBX|3|ST|2930655752-8^Surgical0^Clinical procedure^LNinformation^LN|1.1.21|RadicalR Colon prostatectomycancer||||||F OBX|4|ST|5575257723-0^Clinical9^Pathology Accession information^LNnumber^LN|1.1.4|PCa G6 - prostate and seminal vesicles - left and right pelvic nodes - pre-prostatic fat - left apical margin - left lateral margin||2|89671-16MP||||||F OBX|5|NMST|285722027-1^Pre-biopsy7^Operating serumsurgeon PSA^LNname^LN|1.1.6|5.9|ug/L^^ISO+3|Dr Dayoub||||||F OBX|6|STCE|LN33725-RCPA-00085^Relevant clinical information for clinicopathological staging^LN3^Tumour location^LN|1.1.8|Core biopsy Gleason score: 3+3=67|32713005^Caecum^SCT||||||F OBX|7|STCE|5772329306-9^Pathology8^Type accessionof number^LNoperation^LN|1.1.9|89470-15MP10|235326000^Right hemicolectomy^SCT||||||F OBX|8|ST|18600-7^Principal clinician^LN81169-5^Surgeon's opinion on the existence of local residual cancer postsurgery^LN|1.1.1013|DrNot Smithstated||||||F OBX|9|CEST|70949-3^^LN^CLUSTER^^EN 13606|1.2|70949-3^Macroscopic findings^LNLN-RCPA-00064^Involvement of adjacent organs^LN|1.1.14|Not stated||||||F OBX|10|NMST|29638-4^Specimen weight^LNLN-RCPA-00065^Regional (local) recurrence or distant metastasis^LN|1.21.116|60Not stated|g^^ISO+|||||F OBX|11|CE|70949-3^^LN^CLUSTER^^EN 13606|1.2.2|LN70949-RCPA-00086^Specimen dimensions (prostate)^LN3^Macroscopic findings^LN||||||F OBX|12|NM|LN-RCPA-00100^Length^LN00066^Specimen length^LN|1.2.2.1|51113|mm^^ISO+|||||F OBX|13|NMCE|LN-RCPA-00101^Width^LN33725-3^Tumour site^LN|1.2.2.2|4732713005^Caecum^SCT|mm^^ISO+|||||F OBX|14|NM|LN-RCPA-00102^Thickness^LN21889-1^Maximum tumour diameter^LN|1.2.2.3|4243|mm^^ISO+|||||F OBX|15|CENM|LN81175-RCPA-00087^Seminal vesicles^LN|1.2.3|at0196^Present^99A-F4ADB3A91A896333||||||F
OBX|16|CE|LN-RCPA-00088^Lymph nodes^LN2^Distance of tumour to the nearer proximal or distal 'cut end'^LN|1.2.4|52101004^Present^SCT35|mm^^ISO+|||||F OBX|1716|CENM|20228-3^Laterality^LNLN-RCPA-00067^Distance to nonperitonealised circumferential margin^LN|1.2.5|51440002^Bilateral^SCT35|mm^^ISO+|||||F OBX|1817|CE|70949LN-RCPA-3^^LN^CLUSTER^^EN00068^Tumour 13606perforation^LN|1.2.6.1|at0024^Site(s) and numbers of lymph nodes^99A-F4ADB3A91A896333|2667000^Absent^SCT||||||F OBX|1918|STCE|39111-0^Site^LNLN-RCPA-00069^Relationship to anterior peritoneal reflection^LN|1.2.6.1.1|Left pelvic7|at0092^Entirely above^99A-4DD10FEE7661CBF6||||||F OBX|2019|NMCE|2189466112-1^Number of LNs from this site^LN4^Lymph nodes^LN|1.2.6.1.2|110|at0224^Received^99A-4DD10FEE7661CBF6||||||F OBX|2120|STCE|3911170949-0^Site3^^LN^CLUSTER^^EN 2^LN|1.2.6.13606|1.3|Right70949-3^Microscopic pelvicfindings^LN||||||F OBX|2221|NMCE|21894LN-RCPA-1^Number of LNs from this site^LN00071^Tumour type^LN|1.2.63.1.4|1|35917007^Adenocarcinoma, NOS^SCT||||||F OBX|2322|STCE|2263433732-0^Additional macroscopic  comments^LN9^Histological grade^LN|1.3.2.8|Volume: 0.6cm3 (3D volume estimate method)399415002^Low grade - well and moderately differentiated^SCT||||||F OBX|2423|CE|70949-3^^LN^CLUSTER^^EN 13606LN-RCPA-00072^Maximum degree of local invasion into or through the bowel wall^LN|1.3.3|70949-3^Microscopic findings^LN395707006^pT3-Tumour invades through muscularis propria into pericolorectal tissues^SCT||||||F OBX|2524|CE|44639-3^Histological tumour type^LN|1.3.1|45410002^Adenocarcinoma (Acinar, usual type)^SCT||||||F
OBX|26|CE|70949-3^^LN^CLUSTER^^EN 13606LN-RCPA-00073^Involvement of the proximal/distal resection ('cut end') margins^LN|1.3.4|at0093^Tumourat0143^Not location^99Ainvolved^99A-F4ADB3A91A8963334DD10FEE7661CBF6||||||F OBX|2725|CE|70949-3^^LN^CLUSTER^^EN 13606LN-RCPA-00075^Status of nonperitonealised circumferential margin (rectal tumours)^LN|1.3.4.4|LN-RCPA-00092^Locations by quadrant^LN8|at0241^Not involved^99A-4DD10FEE7661CBF6||||||F OBX|2826|CE|264176005^Right anterior^SCTNM|LN-RCPA-00076^Microscopic clearance^LN|1.3.4.4.1|31874001^Yes^SCT|9|35|mm^^ISO+|||||F OBX|2927|CE|277593009^Right70949-3^^LN^CLUSTER^^EN posterior^SCT13606|1.3.411.4.2|31874001^Yes^SCT1|70949-3^Lymph node site/s^LN||||||F OBX|3028|CE|264065008^Left anterior^SCTST|21893-3^Number of positive^LN|1.3.411.41.32|31874001^Yes^SCT0||||||F OBX|3129|CEST|277594003^Left posterior^SCT21894-1^Total number of lymph nodes^LN|1.3.411.41.43|31874001^Yes^SCT13||||||F OBX|3230|CE|70949-3^^LN^CLUSTER^^EN 13606LN-RCPA-00077^Isolated extra-mural tumour deposits^LN|1.3.4.5|LN-RCPA-00090^Locations by plane^LN12|2667000^Absent^SCT||||||F OBX|3331|CE|68756004^Apex^SCTLN-RCPA-00078^Apical node involvement^LN|1.3.4.5.1|64100000^No^SCT13|2667000^Absent^SCT||||||F OBX|3432|CE|279704000^Mid^SCT70949-3^^LN^CLUSTER^^EN 13606|1.3.4.5.2|64100000^No^SCT14|70949-3^Venous and small vessel invasion^LN||||||F OBX|3533|CE|36082003^Base of prostate^SCTLN-RCPA-00079^Intramural vein invasion^LN|1.3.414.5.3|64100000^No^SCT|2|at0146^Not identified^99A-4DD10FEE7661CBF6||||||F OBX|3634|CE|70949-3^^LN^CLUSTER^^EN 13606LN-RCPA-00080^Extramural vein invasion^LN|1.3.714.3|372278000^Histological tumour grade^SCTat0149^Not identified^99A-4DD10FEE7661CBF6||||||F OBX|3735|NMCE|4464133739-9^Primary4^Small Gleasonvessel grade^LNinvasion^LN|1.3.714.14|3372265000^Present^SCT||||||F OBX|3836|NMCE|4464233741-7^Secondary0^Perineural Gleason grade^LNinvasion^LN|1.3.7.2|415|at0156^Not identified^99A-4DD10FEE7661CBF6||||||F OBX|3937|CE|385432009^Tertiary Gleason grade not applicable^SCTLN-RCPA-00081^Histologically confirmed distant metastases^LN|1.3.7.416|64100000^No^SCT2667000^Absent^SCT||||||F OBX|4038|FTCE|35266-6^Gleason score^LN^372278000^^SCT81317-0^Relevant coexistant pathological abnormalities^LN|1.3.7.5|3+4=7\.br\Composite Gleason Score (ISUP) 2005): 3+4=7 \.br\Index carcinoma score (ISUP 2005): 3+4=7 % \.br\High Grade (4/5): 5%. \.br\Intraduct carcinoma: Absent.18|260386005^None noted^SCT||||||F OBX|39|CE|70949-3^^LN^CLUSTER^^EN 13606|1.4|70949-3^Ancillary test findings^LN||||||F OBX|40|CE|70949-3^^LN^CLUSTER^^EN 13606|1.4.1|70949-3^Mismatch repair enzymes^LN||||||F OBX|41|CE|50328-4^PMS-2^LN|1.4.1.2|at0195^Normal staining^99A-4DD10FEE7661CBF6||||||F OBX|4142|CE|LN50324-RCPA3^MSH-00096^Extent^LN6^LN|1.4.31.9|420366008^Focal^SCT4|at0201^Normal staining^99A-4DD10FEE7661CBF6||||||F OBX|4243|CE|7094943368-3^^LN^CLUSTER^^EN 136060^Microsatellite instablility (MSI)^LN|1.34.1.10|LN-RCPA-00095^Location(s) of EPE^LN6|373121007^Not tested^SCT||||||F OBX|4344|CE|at0138^Lateral^99A-F4ADB3A91A89633358483-9^BRAF (V600E mutation)^LN|1.34.101.1|64100000^No^SCT9|at0208^Not tested^99A-4DD10FEE7661CBF6||||||F OBX|4445|CE|at0139^Postero-lateral^99A-F4ADB3A91A89633321703-4^RAS gene mutation testing^LN|1.34.101.212|64100000^No^SCT373121007^Not tested^SCT||||||F OBX|4546|CE|at0140^Posterior^99A70949-F4ADB3A91A8963333^^LN^CLUSTER^^EN 13606|1.3.10.3|64100000^No^SCT5|70949-3^Synthesis and overview^LN||||||F OBX|4647|CE|at0141^Anterior^99A70949-F4ADB3A91A8963333^^LN^CLUSTER^^EN 13606|1.35.10.4|64100000^No^SCT1|21902-2^Tumour stage (AJCC 2010)^LN||||||F OBX|4748|CE|at0142^Bladder neck^99A-F4ADB3A91A89633321899-0^T classification^LN|1.35.101.51|64100000^No^SCT395707006^pT3^SCT||||||F OBX|4849|CE|at0143^Apical^99A21900-F4ADB3A91A8963336^N classification^LN|1.35.101.62|64100000^No^SCTat0292^pN0^L||||||F OBX|4950|CE|at0144^Other^99A-F4ADB3A91A896333|1.3.10.7|64100000^No^SCT||||||F
OBX|50|CE|44670-8^MarginLN-RCPA-00084^Residual tumour status^LN|1.35.11|55182004^Not involved^SCT2|at0212^R0^99A-4DD10FEE7661CBF6||||||F OBX|51|CEFT|4462622637-0^Seminal3^Diagnostic vesicles^LNsummary^LN|1.5.3.16|at0160^Not involved^99A-F4ADB3A91A896333||||||F
OBX|52|CE|70949-3^^LN^CLUSTER^^EN 13606|1.3.19|23.02.28965^Lymph node status^RCPA||||||F
OBX|53|NM|44621-1^Number of lymph nodes examined^LN|1.3.19.1|1Diagnostic summary:\.br\Speciment type: Right hemicolectomy\.br\Tumour site: Caecal\.br\Tumour type: Adenocarcinoma\.br\Tumour stage: T3 N0 MX\.br\Completeness of excision: Completely excised\.br\Diagnosis:\.br\Right Colon - Moderately differentiated caecal Adenocarcinoma, T3\.br\Thirteen lymph nodes negative for metastatis (0/13)\.br\Surgical margins clear||||||F 
OBX|54|NM|21893-3^Number of positive lymph nodes^LN|1.3.19.2|0||||||F
OBX|55|CE|59544-7^Lymphovascular invasion^LN|1.3.20|at0171^Not identified^99A-F4ADB3A91A896333||||||F
OBX|56|CE|70949-3^^LN^CLUSTER^^EN 13606|1.4|70949-3^Synthesis and overview^LN||||||F
OBX|57|CE|70949-3^^LN^CLUSTER^^EN 13606|1.4.1|21902-2^Pathological staging (AJCC 7th Ed)^LN||||||F
OBX|58|CE|21899-0^Primary tumour (T)^LN|1.4.1.1|at0176^T2  Organ Confined^L||||||F
OBX|59|CE|70949-3^^LN^CLUSTER^^EN 13606|1.4.2|67203-0^Year and edition of staging system^LN||||||F
OBX|60|ST|at0106^Year^99A-F4ADB3A91A896333|1.4.2.1|AJCC 2005||||||F
OBX|61|ST|at0107^Edition^99A-F4ADB3A91A896333|1.4.2.2|7th Ed||||||F
OBX|62|FT|34574-4^Diagnostic summary^LN|1.4.3|1. Radical prostatectomy: Prostatic adenocarcinoma \.br\2. Left pelvic lymph node: Fibradipose tissue only \.br\3. Right pelvic lymph node: No evidence of malignancy \.br\4. Periprostatic tissue: No evidence of malignancy \.br\5. Left apical margin: No evidence of mailgnancy 6. Left lateral margin: No evidence of malignancy||||||F
OBX|63|ED|PDF^Display format in PDF^AUSPDI||ECLIPSE&ECLIPSE:3.1.8 [win32-i386]&L^application^pdf^Base64^JVBERi0...DQo=||||||F